miRNAs in megakaryocyte literature
| Study . | Findings . |
|---|---|
| Georgantas et al29 | Overexpression of miR-155 in K562 cells caused a block in megakaryocytic differentiation. |
| Garzon et al45 | miRNA profile of in vitro differentiated CD34+ bone marrow cells. Identified miR-130a targets MAFB and miR-10a targets HOXA1. |
| O'Connell et al40 | Overexpression of miR-155 in transplanted bone marrow led to a decrease in erythrocytes, megakaryocytes (MKs), and lymphocytes. |
| Guimaraes-Sternberg et al63 | Calcium release suppresses pre-miR-181a in Meg-01 cells. A miR-181a analog blocked Ca+-induced differentiation and induced apoptosis. |
| Labbaye et al50 | The PLZF transcription factor represses levels of miR-146a, which in turn targets CXCR4 expression. Forced expression or repression alters MK development. |
| Lu et al47 | Expression of miR-150 drives MK-erythroid precurors toward the megakaryocytic fate in murine bone marrow transplant experiments. |
| Barroga et al49 | Thrombopoietin induces expression of miR-150 in UT-7/TPO cells, which in turn, targets expression of the transcription factor c-Myb. |
| Romania et al46 | miR-155 levels decrease during megakaryopoiesis in cultured human cord blood. Enforced expression of miR-155 impairs MK proliferation and development. |
| Hussein et al74 | miRNA profile of laser-dissected MKs from primary myelofibrosis essential thrombocythemia patients. |
| Navarro et al59 | miR-34a is rapidly increased during TPA-induced differentiation of K562 cells into MKs. Overexpression of miR-34a enhances MK differentiation in HSCs and regulates c-Myb expression. |
| Ben-Ami et al60 | TPA induces Runx1 binding to the miR-27a regulatory region and causes an increase in miR-27a in K562 cells. miR-27a, in turn, targets and suppresses Runx1 levels. |
| Giradot et al62 | miR-28 targets the thrombopoietin receptor, MPL. Enforced expression prevents MK differentiation in CD34+ cells and is overexpressed in a fraction of platelets in patients with myeloproliferative diseases. |
| Opalinska et al52 | miR-146a increases during MK development. |
| Starczynowski et al53 | Enforced expression of miR-146a in transduced bone marrow cells has no effect on platelet number. |
| Klusmann et al 61 | miR-125b-2 is overexpressed in Down syndrome, acute megakaryoblastic leukemia. miR-125b-2 overexpression induces proliferation and differentiation of MK and MK/erythroid precursors. |
| Ichimura et al58 | Phorbol myristate acetate treatment in K562 cells increases miR-34a levels. miR-34a, in turn, targets mitogen-activated protein kinase kinase 1 (MEK1) and represses proliferation. |
| Starczynowski et al51 | miR-145 and miR-146a are mediators of the 5q-syndrome phenotype. |
| Study . | Findings . |
|---|---|
| Georgantas et al29 | Overexpression of miR-155 in K562 cells caused a block in megakaryocytic differentiation. |
| Garzon et al45 | miRNA profile of in vitro differentiated CD34+ bone marrow cells. Identified miR-130a targets MAFB and miR-10a targets HOXA1. |
| O'Connell et al40 | Overexpression of miR-155 in transplanted bone marrow led to a decrease in erythrocytes, megakaryocytes (MKs), and lymphocytes. |
| Guimaraes-Sternberg et al63 | Calcium release suppresses pre-miR-181a in Meg-01 cells. A miR-181a analog blocked Ca+-induced differentiation and induced apoptosis. |
| Labbaye et al50 | The PLZF transcription factor represses levels of miR-146a, which in turn targets CXCR4 expression. Forced expression or repression alters MK development. |
| Lu et al47 | Expression of miR-150 drives MK-erythroid precurors toward the megakaryocytic fate in murine bone marrow transplant experiments. |
| Barroga et al49 | Thrombopoietin induces expression of miR-150 in UT-7/TPO cells, which in turn, targets expression of the transcription factor c-Myb. |
| Romania et al46 | miR-155 levels decrease during megakaryopoiesis in cultured human cord blood. Enforced expression of miR-155 impairs MK proliferation and development. |
| Hussein et al74 | miRNA profile of laser-dissected MKs from primary myelofibrosis essential thrombocythemia patients. |
| Navarro et al59 | miR-34a is rapidly increased during TPA-induced differentiation of K562 cells into MKs. Overexpression of miR-34a enhances MK differentiation in HSCs and regulates c-Myb expression. |
| Ben-Ami et al60 | TPA induces Runx1 binding to the miR-27a regulatory region and causes an increase in miR-27a in K562 cells. miR-27a, in turn, targets and suppresses Runx1 levels. |
| Giradot et al62 | miR-28 targets the thrombopoietin receptor, MPL. Enforced expression prevents MK differentiation in CD34+ cells and is overexpressed in a fraction of platelets in patients with myeloproliferative diseases. |
| Opalinska et al52 | miR-146a increases during MK development. |
| Starczynowski et al53 | Enforced expression of miR-146a in transduced bone marrow cells has no effect on platelet number. |
| Klusmann et al 61 | miR-125b-2 is overexpressed in Down syndrome, acute megakaryoblastic leukemia. miR-125b-2 overexpression induces proliferation and differentiation of MK and MK/erythroid precursors. |
| Ichimura et al58 | Phorbol myristate acetate treatment in K562 cells increases miR-34a levels. miR-34a, in turn, targets mitogen-activated protein kinase kinase 1 (MEK1) and represses proliferation. |
| Starczynowski et al51 | miR-145 and miR-146a are mediators of the 5q-syndrome phenotype. |